NCT00391729 - A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

221

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG

ABT-089

Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks

DRUG

Placebo

Subjects will take placebo QD, BID for 4-6 weeks

Trial Locations (23)

10010

New York

10312

Bridgewater

Staten Island

20170

Herndon

27514

Chapel Hill

29405

Charleston

32216

Jacksonville

32751

Maitland

33173

Miami

33606

Tampa

38119

Memphis

44124

Lyndhurst

48336

Farmington Hills

53562

Middleton

67114

Newton

68198

Omaha

77566

Lake Jackson

80212

Denver

85210

Mesa

92056

Oceanside

92103

San Diego

94549

Lafayette

97210

Portland